Attend

Facilitate Live is very pleased to welcome you to our upcoming 2nd Decentralized & Hybrid Clinical Trials World Congress 2026 Europe 

DCTs continue to transform the landscape of clinical research by enabling studies to be conducted beyond traditional trial sites. This flexible approach allows participants to complete study activities from home, local healthcare facilities, or nearby laboratories reducing or eliminating the need to travel to a central research location. Supported by virtual collaboration among investigators and local medical teams, DCTs leverage digital health technologies such as mobile applications, wearable devices, telemedicine, video consultations, and home health visits. Together, these innovations expand access to diverse participant populations and accelerate the collection of high-quality real-world data in a more cost-effective and patient centric manner.

As decentralized protocols gain global traction, they are redefining patient engagement by offering greater flexibility and choic —particularly valuable for individuals with rare conditions, mobility limitations, or those living in remote areas. The advantages of DCTs are far reaching, including reduced barriers to participation, improved diversity and inclusion in clinical trials, enhanced recruitment and retention, opportunities to study low-prevalence diseases, shorter development timelines, faster access to innovative therapies, and improved data accuracy—all contributing to more efficient and equitable healthcare delivery.

However, DCTs also bring new considerations. Trial design must address the complexities of data collection, management, and interoperability across multiple digital platforms. Variability in technology use can affect data quality, and participants may face challenges using connected devices correctly. Therefore, researchers must ensure that consent, data entry, and withdrawal processes are intuitive and patient friendly. Strong data privacy and cybersecurity measures are essential to safeguard sensitive information. Ensuring participant safety, managing potential technology failures, and maintaining regulatory compliance across jurisdictions remain critical priorities. Additionally, hybrid approaches should continue to accommodate participants who prefer in person visits or require additional support using digital tools.

The 2nd Decentralized and Hybrid Trials World Congress 2026 – Europe will convene leading experts, regulators, technology innovators, and patient representatives to discuss strategies, share best practices, and showcase new technologies driving the next phase of decentralized research. Attendees can look forward to an engaging, collaborative, and forward thinking exchange of ideas designed to advance the global adoption and impact of DCTs.

We look forward to welcoming you to the Decentralized & Hybrid Clinical Trials World Congress 2026 Europe.